

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A liposomal topotecan unit dosage form, said unit dosage form comprising:

a lipid; and

a topotecan dosage of from about 0.01 mg/M²/dose to about 7.5 mg/M²/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

2. (Previously Presented) The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

3. (Canceled)

4. (Previously Presented) The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a molar ratio of about 70:30 to about 40:45.

5. (Original) The liposomal topotecan unit dosage form of claim 1, comprising from about 1 mg/M²/dose to about 4 mg/M²/dose of topotecan.

6. - 26. (Canceled)

27. (New) A method of treating a solid tumor in a human afflicted therewith, said method comprising administering to said human an effective amount of a topotecan dosage of claim 1 in a pharmaceutically acceptable carrier.

28. (New) The method of claim 27, wherein said solid tumor is selected from the group consisting of solid tumors of the lung, mammary, and colon.

29. (New) The method of claim 27, further comprising administration of a treatment for neutropenia or platelet deficiency.

30. (New) A method of treating solid tumors in a mammal, said method comprising:

administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 mg/M²/dose to about 7.5 mg/M²/dose of topotecan for an interval regime.

31. (New) The method of treating solid tumors of claim 30, wherein said interval regime is at least once a week.

32. (New) The method of treating solid tumors of claim 30, wherein said interval regime is at least once every two weeks.

33. (New) The method of treating solid tumors of claim 30, wherein said interval regime is at least once every three weeks.

34. (New) The method of treating solid tumors of claim 30, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of about 0.05 to about 0.2.

35. (New) The method of treating solid tumors of claim 30, wherein said interval regime is once a day for at least two consecutive days.

36. (New) A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from about 0.015 mg/M²/dose to about 1 mg/M²/dose and having a drug:lipid ratio by weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

37. (New) The liposomal topotecan unit dosage form of claim 1, wherein said topotecan dosage is from 0.01 mg/M²/dose to 7.5 mg/M²/dose and wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of 0.05 to 0.2.

38. (New) The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is 0.05 to 0.15.

39. (New) The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a molar ratio of 70:30 to 40:45.

40. (New) The liposomal topotecan unit dosage form of claim 1, comprising from 1 mg/M²/dose to 4 mg/M²/dose of topotecan.

41. (New) The method of treating solid tumors of claim 30, wherein said liposomal topotecan formulation comprises from 0.01 mg/M²/dose to 7.5 mg/M²/dose.

42. (New) The method of treating solid tumors of claim 30, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of 0.05 to 0.2.

43. (New) A liposomal camptothecin unit dosage form of claim 36, wherein said camptothecin dosage is from $0.015 \text{ mg/M}^2/\text{dose}$ to $1 \text{ mg/M}^2/\text{dose}$ and said drug:lipid ratio by weight is 0.05 to 0.2.